Skip to Content

ALS Ltd - Stock Quote ALQ

Rating as of

Morningstar's ALS Ltd Stock Analysis

Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


No-Moat ALS Ups Fiscal 2022 Earnings Guidance by 6%. FVE Increased to AUD 6.10

Mark Taylor Senior Equity Analyst

Analyst Note

| Mark Taylor |

We increase our fair value for no-moat materials testing specialist ALS by 3% to AUD 6.10. Some is due to time value of money, though a stronger than expected 6% fiscal 2022 underlying NPAT guidance increase to between AUD 260 million and AUD 265 million helps. Our fiscal 2022 underlying NPAT forecast increases by 10% to the new guidance midpoint. We were at the midpoint of the previous guidance range on a like-for-like basis--ALS excluding goodwill amortisation.

Read Full Analysis

ALS Ltd's Company Profile

Business Description

Founded in the 1880s and listing on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS commodities traditionally generated the majority of underlying earnings, providing geochemistry, metallurgy, inspection and mine site services for the global mining industry. Expansion into environmental, pharmaceutical and food testing areas and commodity price weakness have lessened earnings exposure to commodities.

32 Shand Street, Stafford
Brisbane, QLD, 4053, Australia
T +61 733677900
Sector Industrials
Industry Consulting Services
Most Recent Earnings
Fiscal Year End Mar 31, 2022
Stock Type
Employees 15,912